Frozen chemistry controls bacterial infections
By sciencedaily.com
Chemists and molecular biologists have made an unexpected discovery in infection biology. The researchers can now show that two proteins that bind to one another slow down a chemical reaction central to the course of the disease in the bacteria Yersinia pseudotuberculosis. The results have been published in the Journal of Biological Chemistry.
"The discovery paves way for new insights in the regulation of bacterial virulence. The results have given us a new opportunity to study the pathogenic ability in bacteria," says Magnus Wolf-Watz, researcher at the Department of Chemistry at Umeå University, who led the study together with Hans Wolf-Watz, professor at the Department of Molecular Biology.
Yersinia pseudotuberculosis and many similar bacteria infect humans by injecting toxins, so-called effector proteins, through a needle-like organelle called injectisome. Previous research has already shown that the protein YscU plays an important part in the regulation of effector protein transportation. YscU is unique in its ability to cleave itself in two parts, as a consequence, one of these parts is then transported out through the injectisome.
By combining biological experiments with studies on atomic level, the research team discovered that another protein, YscP, binds to YscU and regulates its self-cleaving abilities. When the proteins bound to one another, the speed of the self-cleaving was greatly reduced.
"The chemical process behind the self-cleaving was cooled down by the interaction and was hence slowed down. The result is a good example of how biology and chemistry nearly always go hand in hand and is a huge step forward. This gives us new opportunities to study the regulation of the course of diseases," says Hans Wolf-Watz.
The studies on atomic level were conducted using magnetic resonance spectroscopy at the Department of Chemistry at the NMR for Life platform, which is a national infrastructure for NMR in Sweden.
"The initial investment to fund an NMR instrument that the Kempe Foundations facilitated paved way for further funding from both the Wallenberg Foundations and SciLifeLab. Also, the protein expertise platform in our labs was of crucial importance for undertaking the research project," says Magnus Wolf-Watz.
Source: https://www.sciencedaily.com/releases/2017/03/170303100420.htm
Thursday, May 28, 2026
Postpartum Depression: Recognition and Support
Postpartum depression is a serious but treatable mental health condition that affects approximately one in seven women after childbirth. It is distinct from the baby blues, a milder and much more common experience of mood swings, sadness, and emotional reactivity that affects up to 80 percent of new mothers in the first two weeks after delivery. Postpartum depression is more persistent, more severe, and can significantly interfere with a mother's ability to care for herself and her baby without treatment. Symptoms of postpartum depression include persistent sadness or depressed mood, loss of interest or pleasure in activities previously enjoyed, feelings of worthlessness or guilt, difficulty bonding with the baby, withdrawal from family and friends, changes in sleep and appetite beyond those expected with a newborn, difficulty concentrating, fatigue beyond typical new parent tiredness, and thoughts of harming oneself or the baby. Symptoms typically develop within the first few weeks after delivery but can emerge up to a year postpartum. Risk factors for postpartum depression include a personal or family history of depression or other mental health conditions, previous postpartum depression, stressful life events during pregnancy or after delivery, lack of social support, breastfeeding difficulties, and having a premature or ill newborn. Hormonal changes after delivery, including a dramatic drop in estrogen and progesterone, are thought to contribute to vulnerability in susceptible individuals. For new mothers managing postpartum depression alongside physical health concerns requiring medications, integrated care is accessible through https://www.amoxilcompharm.com/. Treatment of postpartum depression is effective. Psychotherapy, particularly cognitive behavioral therapy and interpersonal therapy, is a first-line treatment. Antidepressant medications are safe and effective and can be used during breastfeeding, with specific medications preferred for their safety profile. Brexanolone, an intravenous treatment, and zuranolone, an oral treatment, have received FDA approval specifically for postpartum depression. Early identification through routine postpartum depression screening at postnatal visits and support from healthcare providers, family, and community resources are essential for recovery. Telehealth expands access to mental health care for new mothers who face significant barriers to in-person appointments. For comprehensive postpartum depression information and maternal mental health resources, visit https://amoxicillina.online/ for accessible patient guidance.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.